Company News
Attovia Therapeutics Gets Bullish Coverage, $30‑45 Targets
Wall Street analysts Citi, Morgan Stanley, and RBC initiated coverage of Attovia Therapeutics, assigning Buy/High Risk, Overweight, and Outperform ratings respectively.
Analysts set price targets of $
